Anika Therapeutics
ANIK
159 hedge funds and large institutions have $613M invested in Anika Therapeutics in 2017 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 58 increasing their positions, 55 reducing their positions, and 16 closing their positions.
304% more call options, than puts
Call options by funds: $3.95M | Put options by funds: $977K
19% more capital invested
Capital invested by funds: $515M → $613M (+$98.2M)
19% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 16
3.46% more ownership
Funds ownership: 80.96% → 84.42% (+3.5%)
2% more funds holding
Funds holding: 156 → 159 (+3)
5% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 55
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
THB Asset Management
Norwalk,
Connecticut
|
+$10.6M |
| 2 |
Bank of New York Mellon
New York
|
+$9.81M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$6.8M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.9M |
| 5 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$4.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$4.98M |
| 2 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
-$3.9M |
| 3 |
CM
Capital Management
Glen Allen,
Virginia
|
-$3.89M |
| 4 |
Millennium Management
New York
|
-$3.77M |
| 5 |
BTW
Boston Trust Walden
Boston,
Massachusetts
|
-$3.65M |
ANIK Hedge Fund Activity: Q2 2017 in Review
159 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Anika Therapeutics (ANIK) for Q2 2017, worth a combined $613M — up 19% from $515M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ANIK positions and 16 closed out — a net gain of 3 holders — while 58 added to existing stakes and 55 trimmed.
The largest buyer was THB Asset Management, opening a new position worth an estimated $10.6M. The largest seller was Renaissance Technologies, cutting an estimated $4.98M.
- 159 institutional investors held Anika Therapeutics (ANIK) as of Q2 2017, up from 156 in Q1 2017.
- Funds reported $613M of Anika Therapeutics stock for Q2 2017, up 19% quarter-over-quarter.
- 19 funds opened new Anika Therapeutics positions in Q2 2017 and 16 closed out, a net change of +3 holders.
- The largest Anika Therapeutics buyer in Q2 2017 was THB Asset Management, an estimated $10.6M added.
- The largest Anika Therapeutics seller in Q2 2017 was Renaissance Technologies, an estimated $4.98M sold.
Based on aggregated 13F filings for Q2 2017.